Grufity logo
Grufity logo
PTPI

PTPI - Petros Pharmaceuticals, Inc. Stock Price, Fair Value and News

00
Market Closed as of 30 Jul 2026, 04:00 pm ET

10/100

PTPI

STOCK SCORE

High Scoring Large Cap stocks have outperformed low scoring stocks by 90% over last 10 years

10/100

PTPI

STOCK SCORE

High Scoring Large Cap stocks have outperformed low scoring stocks by 90% over last 10 years

Price Targets

PTPI Stock Valuation Analysis

Valuation

Login to View

Max Portfolio %

Login to View

PTPI Price Action

Last 30 days

-100%

Last 90 days

-100%

Trailing 12 Months

-100%

PTPI RSI Chart

PTPI Stock Valuation Analysis

Valuation

Login to View

Max Portfolio %

Login to View

PTPI Valuation

Market Cap

0

Price/Earnings (Trailing)

0

Price/Sales (Trailing)

0

EV/EBITDA

1.08

Price/Free Cashflow

0

PTPI Price/Sales (Trailing)

The Good, Bad and Ugly

Growth

Profitability

Size

Dilution Risk

Balance Sheet

Momentum

Funds Popularity

Insider Trading

Price Targets

PTPI Fundamentals

PTPI Revenue

Revenue (TTM)

5.1M

PTPI Earnings

Earnings (TTM)

3.2M

Earnings Growth (Yr)

56.33%

Earnings Growth (Qtr)

-193.32%

PTPI Profitability

EBT Margin

-83.87%

Return on Equity

179.9%

Return on Assets

72.51%

Free Cashflow Yield

0%

PTPI Investor Care

Diluted EPS (TTM)

3.41

Revenue & Growth

How Petros Pharmaceuticals, Inc. generates revenue and covers its expenses, based on the latest reported earnings.

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs(opens in new tab)
Net sales
YearQ1Q2Q3Q4
20245.6M5.5M5.3M5.1M
20236.3M6.7M7.0M5.8M
20227.4M6.9M6.4M6.0M
202111.8M12.9M11.6M7.8M
202014.1M12.6M11.1M9.6M
2019---15.6M
Get all data in R, Python etc through our Historical Stock Data APIs(opens in new tab)

About Petros Pharmaceuticals, Inc.

PTPI
Petros Pharmaceuticals, Inc., a pharmaceutical company, focuses on men's health therapeutics in the United States and internationally. It operates through two segments, Prescription Medications and Medical Devices. The company engages in the commercialization and development of Stendra, an PDE-5 inhibitor prescription medication for the treatment of erectile dysfunction (ED). It also develops and commercializes H100, a novel and patented topical formulation candidate for the treatment of acute Peyronie's disease. The company offers men's health products, including vacuum erection devices, PreBoost, VenoSeal, penile injections, and urinary tract infection tests for the treatment of erectile dysfunction. Petros Pharmaceuticals, Inc. is based in New York, New York.
 WEBSITEpetrospharma.com
 SECTORHealthcare
 INDUSTRYDrug Manufacturers Specialty & Generic
 EMPLOYEES24

Petros Pharmaceuticals, Inc. Frequently Asked Questions

PTPI is the stock ticker symbol of Petros Pharmaceuticals, Inc.. Every public company that trades on a stock exchange gets a ticker symbol.

As of Thu Jul 30 2026, market cap of Petros Pharmaceuticals, Inc. is 0. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

As of Thu Jul 30 2026, PTPI's PE ratio (Price to Earnings) is 0 and Price to Sales (PS) ratio is 0. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. PTPI PE ratio will change depending on the future growth rate expectations of investors.